Total Funding
91
63
Total FundingSeries A raised
Growth Score 91 in past quarter
-1 pts
Heat Score 63 in past quarter
-29 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
30681
Kupando is a biopharmaceutical company that develops agonists to stimulates innate immunity.
Johanna Holldack: CEO & FounderPast Role: Amal Therapeutics, Chairman
About the Company
KUPANDO is a pioneering biopharmaceutical firm that is developing TLR 4/7 agonists to boost innate immunity. The company's mission is to provide cancer patients with not only safe but also inexpensive immunotherapy, as well as to produce immunostimulatory drugs capable of preventing infectious illnesses.